Assessment of Mechanisms Involved in Antinociception Caused by Myrsinoic Acid B
-
- Hess Sarai
- Centro de Ciências da Saúde/Programa de Mestrado em Ciências Farmacêuticas, Universidade do Vale do Itajaí
-
- Padoani Cristina
- Nucleo de Investigações Químico-Farmacêuticas, Universidade do Vale do Itajaí
-
- Scorteganha Laiana Carla
- Nucleo de Investigações Químico-Farmacêuticas, Universidade do Vale do Itajaí
-
- Holzmann Iandra
- Nucleo de Investigações Químico-Farmacêuticas, Universidade do Vale do Itajaí
-
- Malheiros Angela
- Centro de Ciências da Saúde/Programa de Mestrado em Ciências Farmacêuticas, Universidade do Vale do Itajaí Nucleo de Investigações Químico-Farmacêuticas, Universidade do Vale do Itajaí
-
- Yunes Rosendo Augusto
- Departamento de Química, Universidade Federal de Santa Catarina, Campus Universitário Trindade
-
- Delle Monache Franco
- Istituto di Chimica, Università Cattolica
-
- de Souza Márcia Maria
- Centro de Ciências da Saúde/Programa de Mestrado em Ciências Farmacêuticas, Universidade do Vale do Itajaí Nucleo de Investigações Químico-Farmacêuticas, Universidade do Vale do Itajaí
この論文をさがす
抄録
Myrsinoic acid B (AMB) is a prenylated-benzoic acid derivative isolated from the Rapanea genus. Recent studies suggest that AMB has antihyperalgesic and antinociceptive properties in different animal models. The present study was designed to investigate the mechanisms involved in antinociception elicited by AMB (60 mg/kg) when administered by intraperitonial route (i.p.) in mice. The antinociceptive response of the compound was characterized by a reduction in contractions of the abdominal muscle, together with stretching of the hind limbs in response to i.p. injection of acetic acid (0.6%, 0.45 ml/mouse). The antinociception caused by AMB in the acetic acid test was significantly attenuated by i.p. treatment of mice with nitric oxide precursor, (L-arginine, 600 mg/kg), α2 and α1-adrenoceptor antagonists (yohimbine, 0.2 mg/kg/prazosin, 0.2 mg/kg), p-chlorophenylalanine (PCPA) an inhibitor of serotonin synthesis (100 mg/kg), 1-(2-methoxyphenyl)-4-(4-phthalimidobutyl)piperazine (NAN 190), a 5-HT1A selective receptor antagonist (0.5 mg/kg) and a non-selective cholinergic antagonist (atropine, 10 mg/kg). Its action was also modulated by the adrenal-gland hormones. In contrast, antinociception was not affected by naloxone (non-selective opioid receptor antagonist, 1.0 mg/kg), phaclofen (2.0 mg/kg) and bicuculline (1.0 mg/kg) GABAB and GABAA receptor antagonists, respectively, ondansetron (0.3 mg/kg) and ketaserin (1.0 mg/kg), (5-HT3 and 5-HT2 receptors, respectively) and haloperidol (0.2 mg/kg), a non-selective dopaminergic receptor. The antinociceptive effects are not related to muscle-relaxant or sedative action. These results indicate that AMB produces antinociception through mechanisms that involve interaction with L-arginine–nitric oxide, the serotonergic and cholinergic systems, as well as interaction with the α-adrenoceptors.
収録刊行物
-
- Biological & Pharmaceutical Bulletin
-
Biological & Pharmaceutical Bulletin 33 (2), 209-215, 2010
公益社団法人 日本薬学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390001204625560448
-
- NII論文ID
- 130000156626
-
- NII書誌ID
- AA10885497
-
- ISSN
- 13475215
- 09186158
-
- NDL書誌ID
- 10536870
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- NDL
- Crossref
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可